Utidelone Plus Bevacizumab for <i>ERBB2</i>-Negative Metastatic Breast Cancer and Active Brain Metastases
Min Yan(Xi'an University of Science and Technology), Rongguo Qiu, Limin Niu(Zhengzhou University), Chengzheng Wang(Henan Cancer Hospital), Li Tang(Qingdao University), Xinlan Liu(Ningxia Medical University), Huihui Sun(Zhengzhou University), Yuhua Song(Qingdao University), Zhenzhen Liu(Jilin University), Jing Wang(Zhengzhou University), Cuizhi Geng(Hebei Medical University), Shusen Wang(Sun Yat-sen University), Mengwei Zhang(Zhengzhou University), Huimin Lv(Zhengzhou University), Yajing Feng(Zhengzhou University), Huiai Zeng(Zhengzhou University)
Cited by 4
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
|Nature Biotechnology|2018|641
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|477
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
|Nature Immunology|2021|422
Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions
|Proceedings of the National Academy of Sciences|2011|330